title: Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement.
abstract: Novel benzodiazepine-containing gamma-secretase inhibitors for potential use in Alzheimer's disease have been designed that incorporate a substituted hydrocinnamide C-3 side chain. A syn combination of alpha-alkyl or aryl and beta-hydroxy or hydroxymethyl substituents was shown to give highly potent compounds. In particular, (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)butyramide (34) demonstrated excellent in vitro potency (IC(50) = 0.06 nM). 34 could also be selectively methylated to give [(3)H]-28, which is of use in radioligand binding assays.
authors.affiliation: Department of Medicinal Chemistry, The Neuroscience Research Centre, Merck Sharp & Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK. ian_churcher@merck.com
authors.forename: Ian
authors.initials: I
authors.lastname: Churcher
authors.forename: Susie
authors.initials: S
authors.lastname: Williams
authors.forename: Sonia
authors.initials: S
authors.lastname: Kerrad
authors.forename: Timothy
authors.initials: T
authors.lastname: Harrison
authors.forename: José L
authors.initials: JL
authors.lastname: Castro
authors.forename: Mark S
authors.initials: MS
authors.lastname: Shearman
authors.forename: Huw D
authors.initials: HD
authors.lastname: Lewis
authors.forename: Earl E
authors.initials: EE
authors.lastname: Clarke
authors.forename: Jonathan D J
authors.initials: JD
authors.lastname: Wrigley
authors.forename: Dirk
authors.initials: D
authors.lastname: Beher
authors.forename: Yui S
authors.initials: YS
authors.lastname: Tang
authors.forename: Wensheng
authors.initials: W
authors.lastname: Liu
mesh_terms: D053829:Amyloid Precursor Protein Secretases; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D016282:Aspartic Acid Endopeptidases; D001569:Benzodiazepines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001570:Benzodiazepinones / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D010450:Endopeptidases / Q000378:metabolism*; D006801:Humans; D007553:Isotope Labeling; D008024:Ligands; D011480:Protease Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
chemical_list: C475422:3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo(e)(1,4)diazepin-3-yl)butyramide; D016229:Amyloid beta-Peptides; D001570:Benzodiazepinones; D008024:Ligands; D011480:Protease Inhibitors; D001569:Benzodiazepines; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human